Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies

Polycystic ovary syndrome (PCOS) is marked in 30 to 40% by insulin resistance and hyperandrogenism. Myo-inositol (MI) increases insulin sensitivity, decreases hyperandrogenism and improves the menstrual cycle. Its effect during assisted reproductive technologies (ART) has been studied by many author...

Descripción completa

Detalles Bibliográficos
Autores principales: Merviel, Philippe, James, Pandora, Bouée, Sarah, Le Guillou, Mathilde, Rince, Camille, Nachtergaele, Charlotte, Kerlan, Véronique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816413/
https://www.ncbi.nlm.nih.gov/pubmed/33468143
http://dx.doi.org/10.1186/s12978-021-01073-3
_version_ 1783638438097977344
author Merviel, Philippe
James, Pandora
Bouée, Sarah
Le Guillou, Mathilde
Rince, Camille
Nachtergaele, Charlotte
Kerlan, Véronique
author_facet Merviel, Philippe
James, Pandora
Bouée, Sarah
Le Guillou, Mathilde
Rince, Camille
Nachtergaele, Charlotte
Kerlan, Véronique
author_sort Merviel, Philippe
collection PubMed
description Polycystic ovary syndrome (PCOS) is marked in 30 to 40% by insulin resistance and hyperandrogenism. Myo-inositol (MI) increases insulin sensitivity, decreases hyperandrogenism and improves the menstrual cycle. Its effect during assisted reproductive technologies (ART) has been studied by many authors. We conducted a review of the literature on the impact of MI administration in PCOS women in assisted reproductive technologies. Myo-inositol is effective in normalizing ovarian function, improving oocyte and embryo quality in PCOS, however further evaluations by large multicentre randomized controlled trials are needed to assess the clinical pregnancy and live birth rates in ART.
format Online
Article
Text
id pubmed-7816413
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78164132021-01-21 Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies Merviel, Philippe James, Pandora Bouée, Sarah Le Guillou, Mathilde Rince, Camille Nachtergaele, Charlotte Kerlan, Véronique Reprod Health Review Polycystic ovary syndrome (PCOS) is marked in 30 to 40% by insulin resistance and hyperandrogenism. Myo-inositol (MI) increases insulin sensitivity, decreases hyperandrogenism and improves the menstrual cycle. Its effect during assisted reproductive technologies (ART) has been studied by many authors. We conducted a review of the literature on the impact of MI administration in PCOS women in assisted reproductive technologies. Myo-inositol is effective in normalizing ovarian function, improving oocyte and embryo quality in PCOS, however further evaluations by large multicentre randomized controlled trials are needed to assess the clinical pregnancy and live birth rates in ART. BioMed Central 2021-01-19 /pmc/articles/PMC7816413/ /pubmed/33468143 http://dx.doi.org/10.1186/s12978-021-01073-3 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Merviel, Philippe
James, Pandora
Bouée, Sarah
Le Guillou, Mathilde
Rince, Camille
Nachtergaele, Charlotte
Kerlan, Véronique
Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies
title Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies
title_full Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies
title_fullStr Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies
title_full_unstemmed Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies
title_short Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies
title_sort impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816413/
https://www.ncbi.nlm.nih.gov/pubmed/33468143
http://dx.doi.org/10.1186/s12978-021-01073-3
work_keys_str_mv AT mervielphilippe impactofmyoinositoltreatmentinwomenwithpolycysticovarysyndromeinassistedreproductivetechnologies
AT jamespandora impactofmyoinositoltreatmentinwomenwithpolycysticovarysyndromeinassistedreproductivetechnologies
AT boueesarah impactofmyoinositoltreatmentinwomenwithpolycysticovarysyndromeinassistedreproductivetechnologies
AT leguilloumathilde impactofmyoinositoltreatmentinwomenwithpolycysticovarysyndromeinassistedreproductivetechnologies
AT rincecamille impactofmyoinositoltreatmentinwomenwithpolycysticovarysyndromeinassistedreproductivetechnologies
AT nachtergaelecharlotte impactofmyoinositoltreatmentinwomenwithpolycysticovarysyndromeinassistedreproductivetechnologies
AT kerlanveronique impactofmyoinositoltreatmentinwomenwithpolycysticovarysyndromeinassistedreproductivetechnologies

Ejemplares similares